Home・Listă Acțiuni・ADMA Biologics Inc

ADMA Biologics Inc

Închisă

SectorSănătate

9.26 4.04

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

8.69

Maxim

9.01

Indicatori cheie
By Trading Economics
Venit	-4.1M 45M
Vânzări	-25M 114M
P/E Medie Sector	12.853 68.51
EPS	0.17
Marjă de profit	39.59
Angajați	640
EBITDA	-4.2M 61M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+113.62% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-370M 2B
Deschiderea anterioară	5.22
Închiderea anterioară	9.26

Sentimentul știrilor

By Acuity

79%

21%

316 / 340 Clasament în Healthcare

ADMA Biologics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3 aug. 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31 iul. 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30 iul. 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29 iul. 2026, 18:17 UTC

News

Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28 iul. 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27 iul. 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24 iul. 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 iul. 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 iul. 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 iul. 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Comparație

Modificare preț

ADMA Biologics Inc Așteptări

Obiectiv de preț

By TipRanks

113.62% sus

Prognoză pe 12 luni

Medie 18.67 USD 113.62%

Maxim 21 USD

Minim 17 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruADMA Biologics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor ADMA Biologics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

316 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.